Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth Submits NDA and MAA for Cancer Drug | Contract Pharma

What are you searching for?

Sign in

Wyeth Submits NDA and MAA for Cancer Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth Pharmaceuticals has submitted an NDA to the FDA and a marketing authorization application (MAA) to the EMEA for Torisel for the treatment of patients with advanced renal cell carcinoma (RCC).

The registration dossier contains interim data from a Phase III trial of 626 patients who had received no prior systemic therapy. The primary end point of the study was overall survival. The results showed treatment with Torisel increased median survival by 3.6 months, or 49%, compared with treatment with interferon-alpha (10.9 months vs. 7.3 months). The final analysis will also be submitted to regulatory authorities at a future date.

Torisel is an investigational drug that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, a protein that regulates cell proliferation, cell growth and cell survival. If approved, Torisel would be the first agent in this class indicated for the treatment of a cancer.

In July 2004, the FDA granted fast track designation for Torisel for first-line poor prognosis subjects with advanced RCC, and in December 2004 it was granted orphan drug designation for the treatment of RCC. In March 2006, Torisel received Orphan Medicinal Product designation for the treatment of RCC in the EU.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters